What biosafety levels of containment are currently being used for recombinant research with 1918 influenza viruses, highly pathogenic avian influenza viruses, and SARS-CoV?
At the safety symposium, several investigators presented current research and provided examples of risk assessments performed to determine containment for this type of research. A webcast of the presentations at the safety symposium is available here. Dr. Y. Kawaoka presented research with HPAI and 1918 influenza virus, Dr. A. Garcia-Sastre on 1918 influenza virus, Drs. R. Webster and K. Subbarao on HPAI, and Dr. R. Baric on SARS-CoV research.
Related Questions
- What biosafety levels of containment are currently being used for recombinant research with 1918 influenza viruses, highly pathogenic avian influenza viruses, and SARS-CoV?
- What biosafety levels of containment do the NIH Guidelines and BMBL recommend for research with influenza viruses and SARS-CoV?
- What technologies are being used to grow pandemic influenza viruses to make vaccines?
